Zacks Investment Research
29 Jan 2026, 18:20 UTC · 40w ago
CONMED Stock Up Post Q4 Earnings and Revenue Beat, Gross Margin Up
Impact · against what's priced in
CONMED shares are reacting positively to a Q4 beat on both the top and bottom lines, driven by strong international growth and orthopedic surgery strength. While the earnings beat is a positive catalyst, the slight decline in U.S. General Surgery sales suggests a pocket of weakness in domestic OEM products.
- CNMD+0.40
No priced-in read yet
- In context
CONMED reported a Q4 adjusted EPS of $1.43 (8.6% beat) and revenues of $373.2 million (1.9% beat), supported by 17% international growth and strength in Orthopedic Surgery.
Read from the article alone
Search tags
